PMID- 35945549
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20220813
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Aug 9
TI  - Sodium selenite inhibits proliferation and metastasis through ROS-mediated NF-kappaB 
      signaling in renal cell carcinoma.
PG  - 870
LID - 10.1186/s12885-022-09965-8 [doi]
LID - 870
AB  - BACKGROUND: Sodium selenite (SSE) has been reported to exert anti-tumor effects 
      in several cancer cells. However, the underlying mechanisms in renal cancer are 
      yet to be elucidated. The effects of SSE on the proliferation, metastasis, and 
      apoptosis of renal cancer cells, as well as its mechanism, were investigated in 
      this study. METHODS: ACHN and 786-O renal cancer cells were treated with 
      different concentrations of SSE, MTT, and colony formation assays were used to 
      detect the proliferation ability of cells. The migration of cells was detected 
      using scratch-wound-healing and transwell-migration assays. The effect of SSE on 
      apoptosis was assessed by AnnexinV-FITC/PI double staining. Besides, Western 
      blotting was employed to detect the protein-expression level and elucidate the 
      underlying pathways. We also made subcutaneous xenografts in athymic mice to 
      verify the effect of SSE on tumor growth in vivo. RESULTS: Our results 
      demonstrated that treatment with SSE resulted in significant inhibition of cell 
      proliferation and migration. Flow cytometry and Western blot confirmed that SSE 
      induced apoptosis via the endogenous apoptotic pathway. We also confirmed that 
      SSE treatment causes an increase in intracellular reactive oxygen species (ROS) 
      levels, resulting in the inhibition of nuclear transcription factor-kappaB (NF-kappaB) 
      signaling. Modulation of the ROS level by the chemical inhibitor 
      N-acetyl-cysteine reversed the effect of SSE on cells. Similarly, subcutaneous 
      xenografts in athymic mice models showed that SSE inhibits tumor growth in vivo. 
      CONCLUSION: These results indicate that SSE inhibits proliferation and migration 
      and induces apoptosis via ROS mediated inhibition of NF-kappaB signaling in renal 
      cancer cells.
CI  - (c) 2022. The Author(s).
FAU - Liu, Xiao
AU  - Liu X
AD  - Department of Urology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, Shandong, China.
AD  - Department of Urology, Zoucheng People's Hospital, Zoucheng, 273500, Shandong, 
      China.
FAU - Jiang, Meng
AU  - Jiang M
AD  - Department of Orthopaedics, Zoucheng People's Hospital, Zoucheng, 273500, 
      Shandong, China.
FAU - Pang, Chenggang
AU  - Pang C
AD  - Department of Orthopaedics, Zoucheng People's Hospital, Zoucheng, 273500, 
      Shandong, China.
FAU - Wang, Jianning
AU  - Wang J
AD  - Department of Urology, Shandong Provincial Qianfoshan Hospital, Shandong 
      University, Jinan, 250014, Shandong, China. docjianningwang@163.com.
FAU - Hu, Lijuan
AU  - Hu L
AD  - Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM 
      Repair, Institute of Acute Abdominal Diseases of Integrated Traditional Chinese 
      and Western Medicine, Tianjin Nankai Hospital, Nankai Clinical College, Tianjin 
      Medical University, Tianjin, China. hulijuan2014@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220809
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (NF-kappa B)
RN  - 0 (Reactive Oxygen Species)
RN  - HIW548RQ3W (Sodium Selenite)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - *Kidney Neoplasms/drug therapy
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Sodium Selenite/pharmacology/therapeutic use
PMC - PMC9364612
OTO - NOTNLM
OT  - Migration
OT  - NF-kappaB
OT  - Proliferation
OT  - Renal Cancer
OT  - Sodium selenite
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/10 06:00
MHDA- 2022/08/12 06:00
PMCR- 2022/08/09
CRDT- 2022/08/09 23:37
PHST- 2022/05/09 00:00 [received]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2022/08/09 23:37 [entrez]
PHST- 2022/08/10 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2022/08/09 00:00 [pmc-release]
AID - 10.1186/s12885-022-09965-8 [pii]
AID - 9965 [pii]
AID - 10.1186/s12885-022-09965-8 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Aug 9;22(1):870. doi: 10.1186/s12885-022-09965-8.